[go: up one dir, main page]

WO2015013233A3 - Methods and compositions for the treatment and diagnosis of bladder cancer - Google Patents

Methods and compositions for the treatment and diagnosis of bladder cancer Download PDF

Info

Publication number
WO2015013233A3
WO2015013233A3 PCT/US2014/047535 US2014047535W WO2015013233A3 WO 2015013233 A3 WO2015013233 A3 WO 2015013233A3 US 2014047535 W US2014047535 W US 2014047535W WO 2015013233 A3 WO2015013233 A3 WO 2015013233A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treatment
bladder cancer
diagnosis
methods
Prior art date
Application number
PCT/US2014/047535
Other languages
French (fr)
Other versions
WO2015013233A2 (en
Inventor
Karen Chapman
Joseph Wagner
Michael West
Jennifer Lorrie KIDD
Original Assignee
Oncocyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncocyte Corp filed Critical Oncocyte Corp
Publication of WO2015013233A2 publication Critical patent/WO2015013233A2/en
Publication of WO2015013233A3 publication Critical patent/WO2015013233A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides methods, compositions and kits for the detection and treatment of bladder cancer.
PCT/US2014/047535 2013-07-23 2014-07-22 Methods and compositions for the treatment and diagnosis of bladder cancer WO2015013233A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361857333P 2013-07-23 2013-07-23
US61/857,333 2013-07-23

Publications (2)

Publication Number Publication Date
WO2015013233A2 WO2015013233A2 (en) 2015-01-29
WO2015013233A3 true WO2015013233A3 (en) 2015-11-12

Family

ID=52393951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/047535 WO2015013233A2 (en) 2013-07-23 2014-07-22 Methods and compositions for the treatment and diagnosis of bladder cancer

Country Status (1)

Country Link
WO (1) WO2015013233A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214189A1 (en) * 2016-06-06 2017-12-14 Oncocyte Corporation Methods and compositions for detection and diagnosis of bladder cancer
WO2018027091A1 (en) * 2016-08-05 2018-02-08 The Research Foundation For The State University Of New York Keratin 17 as a biomarker for bladder cancer
EP3336547A1 (en) * 2016-12-13 2018-06-20 Lionex GmbH Novel human bladder cancer biomarkers and their diagnostic use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086932A1 (en) * 2007-03-20 2010-04-08 Indas Biotech, S.L.U. Bladder cancer diagnosis and/or prognosis method
US20100131432A1 (en) * 2008-11-17 2010-05-27 Kennedy Giulia C Methods and compositions of molecular profiling for disease diagnostics
US20120083424A1 (en) * 2002-11-01 2012-04-05 Lars Dyrskjot Andersen Expression of UBE2C and Other Genes Associated with Bladder Cancer Progression
US20130183345A1 (en) * 2003-11-03 2013-07-18 Catalyst Assets, Llc Treatment of Bladder Cancer Following Detection of Expression Levels of Certain Progression Markers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083424A1 (en) * 2002-11-01 2012-04-05 Lars Dyrskjot Andersen Expression of UBE2C and Other Genes Associated with Bladder Cancer Progression
US20130183345A1 (en) * 2003-11-03 2013-07-18 Catalyst Assets, Llc Treatment of Bladder Cancer Following Detection of Expression Levels of Certain Progression Markers
US20100086932A1 (en) * 2007-03-20 2010-04-08 Indas Biotech, S.L.U. Bladder cancer diagnosis and/or prognosis method
US20100131432A1 (en) * 2008-11-17 2010-05-27 Kennedy Giulia C Methods and compositions of molecular profiling for disease diagnostics

Also Published As

Publication number Publication date
WO2015013233A2 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
IL252796B (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
WO2014116833A3 (en) Compositions and methods for detecting neoplasia
WO2015153513A8 (en) Anti-ox40 antibodies and methods of use
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
WO2015066452A3 (en) Methods of treating pediatric cancers
EP3258966A4 (en) Methods, compositions, and kits for treatment of cancer
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2014071067A3 (en) Treatment and diagnosis of colon cancer
WO2015179835A3 (en) Mit biomarkers and methods using the same
EP3469101A4 (en) Methods and compositions for prostate cancer diagnosis and treatment
WO2015187727A3 (en) Molecular mammography
WO2017181163A3 (en) Methods and compositions for detection and diagnosis of breast cancer
WO2016094374A8 (en) Compositions and methods for treatment of friedreich's ataxia
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
WO2017187343A3 (en) Nanoemulsions and methods for cancer therapy
WO2017103280A9 (en) Intravesical therapy for bladder cancer
HK1220197A1 (en) 5-bromo-indirubins
EP3292218A4 (en) Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
WO2015013233A3 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
WO2015042446A3 (en) Compositions and methods for the analysis of radiosensitivity
EP3189161A4 (en) Methods for diagnosis, prognosis and methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14829279

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14829279

Country of ref document: EP

Kind code of ref document: A2